AstraZeneca Pharma India opens new Mumbai corporate office

Compliance View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹5932.00

prior close

₹5960.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.7%+4.1% vs market

Pharmaceuticals peers, median of 172sector-1.6%+4.0% vs sector

On the reaction day the stock moved 4.1 pts more than Nifty Microcap 250 and 4.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.5

15m

-0.9

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.4-1.7+4.1-1.6+4.0

Next day

+2.2-4.2+6.5-3.5+5.7

+1.5-5.2+6.7-3.8+5.3

+1.3-7.4+8.7-5.3+6.6

+2.0-7.0+9.0-4.1+6.1

+2.9pendingpending-2.4+5.3

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

AstraZeneca Pharma India opened a new 25,600 sq ft corporate office in Mumbai, inaugurated by Maharashtra Chief Minister Devendra Fadnavis. The company has launched over 25 new medicines in India in the past three years and runs about 80 global clinical trials locally. With around 5,000 employees, it focuses on Oncology, Biopharmaceuticals and Rare Disease. The move signals an expansion phase to deepen partnerships and improve access to innovative therapies.

Likely market impact

Shows company commitment to India expansion, supporting future growth in sales and clinical research. Likely neutral for stock in the short term.